Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of 0.05% atropine on visual function in progressive myopia
ACTRN12622001374752Phase 3Not yet recruiting
- Sponsor
- University of New South Wales
- Start
- Nov 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atropine in myopia, sponsored by University of New South Wales. Primary endpoints: Change in colour contrast sensitivity function, Change in contrast sensitivity function and 1 more. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
atropine
03
Conditions
myopia
Beyond the preview
Go deeper on ACTRN12622001374752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622001374752.